Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

A20 cells

From Wikipedia, the free encyclopedia
(Redirected from A20 leukemia cell)

A20 cells, also called ATCC TIB-208, is a cell line originally derived from B-cell lymphoma in an old BALB/c mouse.[1] A20 cells are BALB/c lymphoma cells derived from spontaneous reticulum cell neoplasm.[2] ATCC TIB-208 cells originated from B-cell lymphoma in the reticulum cell sarcoma of an elderly BALB/c mouse.[3] A20 cells are used in medical research such as drug screening or vaccine target selection.[4][5][6] A20 cells are also highly responsive to immunomodulatory antibodies, and are therefore used frequently in immunotherapy drug studies.[3]

References

[edit]
  1. Kim, KJ; Kanellopoulos-Langevin, C; Merwin, RM; Sachs, DH; Asofsky, R (1979). "Establishment and characterization of BALB/c lymphoma lines with B cell properties". Journal of Immunology. 122 (2): 549–554. doi:10.4049/jimmunol.122.2.549. PMID 310843.
  2. Priem, Dario; van Loo, Geert; Bertrand, Mathieu J. M. (2020-05-01). "A20 and Cell Death-driven Inflammation". Trends in Immunology. 41 (5): 421–435. doi:10.1016/j.it.2020.03.001. ISSN 1471-4906. PMID 32241683. S2CID 214771288.
  3. 1 2 "A20: Modeling B cell lymphoma in mice". drugdevelopment.labcorp.com. Retrieved 2022-12-05.
  4. Meziane el, K; Bhattacharyya, T; Armstrong, AC; Qian, C; Hawkins, RE; Stern, PL; Dermime, S (2004-10-10). "Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma". International Journal of Cancer. 111 (6): 910–920. doi:10.1002/ijc.20332. PMID 15300803.
  5. Siegel, S; Wagner, A; Kabelitz, D; Marget, M; Coggin J, Jr; Barsoum, A; Rohrer, J; Schmitz, N; Zeis, M (2003-12-15). "Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies". Blood. 102 (13): 4416–23. doi:10.1182/blood-2003-01-0198. PMID 12869512. S2CID 9814435.
  6. Siegel, S; Wagner, A; Schmitz, N; Zeis, M (2003). "Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model". British Journal of Haematology. 122 (6): 911–4. doi:10.1046/j.1365-2141.2003.04535.x. PMID 12956760.
[edit]